HomeCompareENDP vs O

ENDP vs O: Dividend Comparison 2026

ENDP yields 534.19% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENDP wins by $102783.24M in total portfolio value
10 years
ENDP
ENDP
● Live price
534.19%
Share price
$0.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102783.28M
Annual income
$75,120,205,270.55
Full ENDP calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — ENDP vs O

📍 ENDP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENDPO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENDP + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENDP pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENDP
Annual income on $10K today (after 15% tax)
$45,405.98/yr
After 10yr DRIP, annual income (after tax)
$63,852,174,479.97/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, ENDP beats the other by $63,852,170,142.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENDP + O for your $10,000?

ENDP: 50%O: 50%
100% O50/50100% ENDP
Portfolio after 10yr
$51391.66M
Annual income
$37,560,105,186.65/yr
Blended yield
73.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ENDP right now

ENDP
Analyst Ratings
24
Buy
20
Hold
4
Sell
Consensus: Buy
Price Target
$2.00
+434.2% upside vs current
Range: $2.00 — $2.00
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENDP buys
0
O buys
0
No recent congressional trades found for ENDP or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENDPO
Forward yield534.19%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$102783.28M$34.2K
Annual income after 10y$75,120,205,270.55$5,102.74
Total dividends collected$100415.31M$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$2.00$64.00

Year-by-year: ENDP vs O ($10,000, DRIP)

YearENDP PortfolioENDP Income/yrO PortfolioO Income/yrGap
1← crossover$64,119$53,418.80$10,818$608.16+$53.3KENDP
2$388,715$320,107.45$11,787$741.68+$376.9KENDP
3$2,229,591$1,813,666.47$12,946$911.00+$2.22MENDP
4$12,107,940$9,722,278.04$14,345$1,127.94+$12.09MENDP
5$62,298,925$49,343,428.51$16,056$1,409.05+$62.28MENDP
6$303,936,946$237,277,096.11$18,171$1,777.83+$303.92MENDP
7$1,407,082,298$1,081,869,766.45$20,820$2,268.21+$1407.06MENDP
8$6,186,454,865$4,680,876,806.01$24,188$2,929.90+$6186.43MENDP
9$25,853,337,136$19,233,830,430.18$28,533$3,837.11+$25853.31MENDP
10$102,783,276,006$75,120,205,270.55$34,235$5,102.74+$102783.24MENDP

ENDP vs O: Complete Analysis 2026

ENDPStock

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Full ENDP Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this ENDP vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENDP vs SCHDENDP vs JEPIENDP vs KOENDP vs MAINENDP vs STAGENDP vs ADCENDP vs NNNENDP vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.